Business
Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach
Laboratory Stein is part of the Limbach Group, which is the largest network of laboratories in Germany and one of the largest networks of laboratories in
About this update from Quantum Cyber N.v.
[{"type":"text","content":"Laboratory Stein is part of the Limbach Group, which is the largest network of laboratories in Germany and one of the largest networks of laboratories in EuropeLaboratory MVZ Dr. Stein + Kollegen processes over five million samples annually with a team of 500 employees that includes biologists, chemists, doctors and other specialists BERKELEY, Calif. and MAINZ, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Labor MVZ Dr. Stein + Kollegen (“Laboratory Mönchengladbach”). Laboratory Mönchengladbach, one of the largest diagnostics laboratories in the North Rhine-Westphalia region of Germany, will commercialize ColoAlert, Mainz Biomed’s unique, highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). With a team of over 500 employees that includes biologists, chemists, doctors and other specialists, Laboratory Mönchengladbach services over 2500 physicians, processing over five million samples in total annually and screening approximately 1000 patients per week specifically for CRC. “As a result of our unique model of engaging in mutually beneficial commercial partnerships with leading laboratories such as MVZ Dr. Stein + Kollegen, Mönchengladbach, we’re able to quickly and effectively expand our national footprint and enable larger populations to benefit from highly efficient and reliable CRC testing,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We are ideally positioned to further scale operations across Europe and will continue to pursue and engage in beneficial partnerships with the leading diagnostics labs in each jurisdiction being targeted.” Under the terms of the partnership, Mainz Biomed will co-brand ColoAlert with Laboratory Mönchengladbach, and sell its polymerase chain reaction (PCR) assay kits for advanced colorectal cancer detection, on an on-demand basis for use by Labor Mönchengladbach’s network of physicians and their patients. In order to optimize awareness and adoption, Mainz Biomed and Labor Mönchengladbach will also collaborate to deliver a comprehensive marketing and education campaign to include direct-to-consumer advertising, cross channel promotion to physician networks, webinars a...